Bifogade filer
Nanologica Receives Supplementary Order Worth approximately SEK 1.9 Million from Returning Customer in China
Kurs
+1,36%
Likviditet
0,51 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-10-24 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | N/A | Årsstämma |
| 2025-04-17 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-07 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-23 | - | Extra Bolagsstämma 2024 |
| 2024-07-05 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-04-26 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-07 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-10 | - | Bokslutskommuniké 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-09-15 | - | Extra Bolagsstämma 2022 |
| 2022-08-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-03 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2022-06-02 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-08 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-28 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2021-05-27 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-29 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2020-05-28 | - | Årsstämma |
| 2020-02-26 | - | Extra Bolagsstämma 2020 |
| 2020-02-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2019-05-29 | - | Årsstämma |
| 2019-05-10 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-15 | - | Bokslutskommuniké 2018 |
| 2018-11-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-01 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2018-05-31 | - | Årsstämma |
| 2018-04-25 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-02 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2017-06-01 | - | Årsstämma |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-09-12 | - | Extra Bolagsstämma 2016 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-01 | - | X-dag ordinarie utdelning NICA 0.00 SEK |
| 2016-05-31 | - | Årsstämma |
| 2016-05-20 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-11-26 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Nanologica has received a supplementary order for the company's silica-based purification media NLAB Saga® from the customer in China who at the end of September placed an order for NLAB Saga® at a value of approximately SEK 3.7 million. The value of this supplementary order amounts to approximately SEK 1.9 million.
The customer is a pharmaceutical manufacturer that primarily produces peptides including GLP-1 analogues. In June this year, they placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today's order is the third order for NLAB Saga® from the customer.
“The fact that the customer increases the order they placed last week indicates that they are satisfied with the product and have strong confidence that it meets their needs. We look forward to continued good cooperation with this customer. I would also like to pay tribute to our team who have been working intensively with customers in the Chinese market since the beginning of this year, and it is very satisfying to now see that work bear fruit”, CEO Andreas Bhagwani comments.
For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90
About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.
This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-04 13:55 CEST.